Literature DB >> 2425955

Resistance to natural killer cell-mediated cytolysis by a pleiotropic drug-resistant human erythroleukemia (K562-R) cell line.

S Yanovich, R E Hall, C Weinert.   

Abstract

K562-R, a pleiotropic drug-resistant cell line established in vitro, and K562-S, the chemotherapy-sensitive parent line, were used as targets in the natural killer cell (NK) system. At each of the effector:target ratios studied, the K562-R demonstrated a decrease in their susceptibility to both unstimulated and interferon-activated NK cells, as compared to the K562-S line. This difference did not appear to be related to a variable expression of NK target structures, as the number of effector:target conjugates was similar, and both lines competed equally well in cold target inhibition experiments. The K562-R cells were not resistant to complement or monocyte-mediated killing, suggesting a relatively specific resistance to cell-mediated killing. These results are compatible with an NK postbinding defect in the K562-R cells and suggest that greater tumorigenicity for pleiotropic drug-resistant cells may in part be due to altered susceptibility to host defense.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2425955

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Diverse multidrug-resistance-modification agents inhibit cytolytic activity of natural killer cells.

Authors:  A S Chong; P N Markham; H M Gebel; S D Bines; J S Coon
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

2.  Selection of tumor cell variants for resistance to tumor necrosis factor also induces a form of pleiotropic drug resistance.

Authors:  S C Wright; A W Tam; P Kumar
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Drug resistance in rat colon cancer cell lines is associated with minor changes in susceptibility to cytotoxic cells.

Authors:  W Van de Vrie; S A Van der Heyden; E E Gheuens; A M Bijma; E A De Bruijn; R L Marquet; A T Van Oosterom; A M Eggermont
Journal:  Cancer Immunol Immunother       Date:  1993-10       Impact factor: 6.968

4.  Inhibition of cell-mediated cytolysis and P-glycoprotein function in natural killer cells by verapamil isomers and cyclosporine A analogs.

Authors:  W T Klimecki; C W Taylor; W S Dalton
Journal:  J Clin Immunol       Date:  1995-05       Impact factor: 8.317

Review 5.  P-glycoprotein expression and regulation. Age-related changes and potential effects on drug therapy.

Authors:  S Gupta
Journal:  Drugs Aging       Date:  1995-07       Impact factor: 3.923

Review 6.  Human cell lines as models for multidrug resistance in solid tumours.

Authors:  M Clynes; M Heenan; K Hall
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

Review 7.  P-glycoprotein (MDR 1 gene product) in cells of the immune system: its possible physiologic role and alteration in aging and human immunodeficiency virus-1 (HIV-1) infection.

Authors:  S Gupta; S Gollapudi
Journal:  J Clin Immunol       Date:  1993-09       Impact factor: 8.317

8.  Trivanillic polyphenols with anticancer cytostatic effects through the targeting of multiple kinases and intracellular Ca2+ release.

Authors:  Delphine Lamoral-Theys; Nathalie Wauthoz; Petra Heffeter; Véronique Mathieu; Utte Jungwirth; Florence Lefranc; Jean Nève; Jacques Dubois; François Dufrasne; Karim Amighi; Walter Berger; Philippe Gailly; Robert Kiss
Journal:  J Cell Mol Med       Date:  2012-07       Impact factor: 5.310

9.  Inhibition of colony formation of drug-resistant human tumor cell lines by combinations of interleukin-2-activated killer cells and antitumor drugs.

Authors:  A Ohtsu; Y Sasaki; T Tamura; Y Fujiwara; Y Ohe; K Minato; K Nakagawa; M Bungo; N Saijo
Journal:  Jpn J Cancer Res       Date:  1989-03

10.  Cytotoxic and pro-apoptotic action of MjTX-I, a phospholipase A2 isolated from Bothrops moojeni snake venom, towards leukemic cells.

Authors:  Rogério Bodini Benati; Tássia Rafaela Costa; Maira da Costa Cacemiro; Suely Vilela Sampaio; Fabíola Attié de Castro; Sandra Mara Burin
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2018-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.